Eikon Therapeutics is planning to become the second biotech to go public in 2026 in another sign the public markets are looking increasingly attractive to drug developers. Eikon emerged publicly in ...

Eikon Therapeutics, Inc. (EIKN) has filed to raise development capital in an IPO of its common stock, according to SEC S-1 registration information. The company is a large biopharma firm developing ...

Eikon Therapeutics Inc. filed for an initial public offering to help fund its advanced pipeline of cancer drugs. The company plans for its shares to trade on the Nasdaq Global Market under the symbol ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon's leadership team includes ...

With countless applications and a combination of approachability and power, Python is one of the most popular programming languages for beginners and experts alike. We’ve compiled a list of 10 online ...

Jan 9 (Reuters) - Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering in the United States. Eikon Therapeutics is a late-stage clinical ...

Eikon Therapeutics filed for an initial public offering. The late-stage clinical biopharmaceutical company didn't disclose in its Friday filing the price or amount of shares it would offer. It intends ...

All websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings ...

Quant funds have had a tough start to the year. The average quant started the year down 1%, according to Goldman Sachs. Managers such as Renaissance Technologies and Schonfeld have lost money in ...

Eikon Therapeutics has filed for an IPO, in what would be a bellwether for whether the optimism that has rallied the biotech market can also support IPO prospects for some of the largest still-private ...

2026 has so far resembled the worst parts of 2025 at many quant hedge fund managers. The beginning of the year had the worst stretch of losses since early October, according to a Goldman Sachs report, ...